NCT03466983View on ClinicalTrials.gov

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions
IBD
Interventions
DRUG

Iron Isomaltoside

administered IV

DRUG

Ferric Carboxymaltose

administered IV

Trial Locations (1)

8600

Pharmacosmos Investigational Site, Silkeborg

Sponsors

Lead Sponsor

Pharmacosmos A/S
All Listed Sponsors
lead

Pharmacosmos A/S

INDUSTRY

NCT03466983 - A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter